Edward Hai Dhow Liao

Title: Edward Hai Dhow Liao: Innovator in T Cell Therapy

Introduction

Edward Hai Dhow Liao is a prominent inventor based in Petaluma, California. He has made significant contributions to the field of immunotherapy, particularly in the development of T cell therapies. His innovative work has the potential to impact cancer treatment and enhance patient outcomes.

Latest Patents

Liao holds a patent for TACI binding molecules. This patent includes antibodies, fragments thereof, chimeric antigen receptors (CARs), and T cell receptors (TCRs) that comprise one or more of the dual TACI-BCMA binding domains. The patent also covers compositions, cells, and cell therapies that utilize these binding domains, along with methods of treatment.

Career Highlights

Edward Liao is currently associated with Kite Pharma, Inc., a leading company in the field of cell therapy. His work at Kite Pharma focuses on advancing innovative therapies that harness the power of the immune system to fight cancer. Liao's expertise and dedication have positioned him as a key figure in the development of cutting-edge treatments.

Collaborations

Liao collaborates with notable colleagues, including Jonathan Belk and Eugene Bolotin. These partnerships enhance the research and development efforts at Kite Pharma, fostering an environment of innovation and discovery.

Conclusion

Edward Hai Dhow Liao is a distinguished inventor whose work in T cell therapy is paving the way for new cancer treatments. His contributions to the field are invaluable, and his ongoing research promises to bring hope to many patients.